Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
10.6M
-
Number of holders
-
20
-
Total 13F shares, excl. options
-
4.13M
-
Shares change
-
+243K
-
Total reported value, excl. options
-
$1.29M
-
Value change
-
-$1.72M
-
Number of buys
-
8
-
Number of sells
-
-8
-
Price
-
$0.31
Significant Holders of Aridis Pharmaceuticals, Inc. - Common Stock (ARDS) as of Q1 2023
24 filings reported holding ARDS - Aridis Pharmaceuticals, Inc. - Common Stock as of Q1 2023.
Aridis Pharmaceuticals, Inc. - Common Stock (ARDS) has 20 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4.13M shares
of 10.6M outstanding shares and own 38.89% of the company stock.
Largest 10 shareholders include SABBY MANAGEMENT, LLC (2.14M shares), COMMONWEALTH EQUITY SERVICES, LLC (646K shares), VANGUARD GROUP INC (525K shares), Roumell Asset Management, LLC (447K shares), GEODE CAPITAL MANAGEMENT, LLC (143K shares), STATE STREET CORP (43.2K shares), PRUDENTIAL FINANCIAL INC (37.6K shares), ACADIAN ASSET MANAGEMENT LLC (36.5K shares), NORTHERN TRUST CORP (28.1K shares), and SUSQUEHANNA INTERNATIONAL GROUP, LLP (23.1K shares).
This table shows the top 20 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.